Právní předpis byl sestaven k datu 19.09.2014.
Zobrazené znění právního předpisu je účinné od 20.12.2013 do 19.09.2014.
98
XXXXXXX
Xxxxxxxxxxxx xxxxxxxxxxxx xxxx,
xxxxxx xx xxxx x xxxxxxxx sdělení Xxxxxxxxxxxx xxxxxxxxxxxx věcí x. 58/2007 Xx. x. s. x x. 46/2008 Sb. x. x. x xxxxxxxxx sdělení Xxxxxxxxxxxx xxxxxxxxxxxx xxxx č. 97/2012 Sb. x. x. o Xxxxxxxxxxx xxxxxx xxxxx dopingu xx sportu
Xxxxxxxxxxxx xxxxxxxxxxxx xxxx xxxxxxx, že dne 12. xxxxxxxxx 2012 xxxx xxxxxxxxx ředitelkou XXXXXX xxxxxxxx schválení xxxxxx znění Přílohy X - Seznamu xxxxxxxxxx látek a xxxxx - Mezinárodní xxxxxxxx Mezinárodní xxxxxx xxxxx xxxxxxx xx xxxxxx1).
S xxxxx xxxxxx Přílohy X xxxxxxxx xxxxxxx Xxxxxxxxx Xxxxx republiky.
Xxxx xxxxx Xxxxxxx X xxxxxxxxx x xxxxxxxx x souladu s xxxxxxx 34 xxxx. 3 Úmluvy xxx 1. ledna 2013 x xxxxx xxxx xxxxxxxxx x xxxxxxxx x pro Českou xxxxxxxxx. Xxxx xxxxxx xxxxxx xxxxx Xxxxxxx X v platnost xxxxxxxx xxxxxx xxxxx Xxxxxxx X Xxxxxxxxxxx xxxxxx xxxxx dopingu xx xxxxxx platné xx 1. ledna 2012 x xxxxxxxxx xxx č. 97/2012 Sb. m. s.
Anglické xxxxx Xxxxxxx X x xxxx xxxxxxx xx xxxxxxx xxxxxx xx xxxxxxxxx současně.
1) Xxxxxxxxxxx xxxxxx xxxxx xxxxxxx xx xxxxxx xxxxxxx xxx 19. xxxxx 2005 x Paříži xxxx xxxxxxxxx xxx č. 58/2007 Sb. m. s. a č. 46/2008 Sb. m. s.
PŘÍLOHA X
XXXXXX XXXXXXXXXX XXXXX X METOD XXXXXXX XXX XXX 2013
XXXXXXX XXXXXXXXXXXXX XXXXX
Xxxxxx od 1. xxxxx 2013
Xxxxx xxxxxx 4.2.2 Xxxxxxxxx xxxxxxxxxxxxxxx xxxxxx všechny Xxxxxxxx látky xxxxx xxxxxxxxxx xx "Xxxxxxxxxx xxxxx" xxxxx xxxxx xx xxxxxx X1, X2, X4.4, X4.5 x S6(a) x Xxxxxxxxxx metod M1, X2 a M3.
|
LÁTKY X XXXXXX XXXXXXXX XXXXX
(XXX SOUTĚŽI X XXXX SOUTĚŽ)
|
XXXXXXXX LÁTKY
X0. XXXXXXXXXXX XXXXX
Xxxxxxxxx xxxxxxxxxxxxx látka, která xxxx xxxxxxxx x xxxxxxxxxxxxx xxxxxxx Xxxxxxx x xxxx xxxxxxxx xxxxxxxxx xxx humánní xxxxxxxxxxxx xxxxxxx xxxxxxxxxx xxxxxxx xxxxxxxxxxxxx xxxxxxxxxx xxxxxx (xxxx. léčiva x preklinickém xxxx xxxxxxxxx xxxxxx výzkumu xxxx xx xxxxxxxx xxxxxxxxxx, xxxxxxxxxx drogy, xxxxxxxxxxx xxxx), xx xxxxxxxx stále.
S1. XXXXXXXXXX XXXXX
Anabolické xxxxx xxxx zakázány.
1. ANDROGENNÍ XXXXXXXXXX XXXXXXXX (XXX):
(a) Xxxxxxxx* XXX, xxxxxxxxxx:
1-xxxxxxxxxxxxx (5α-androst-1-en-3β,17β-diol); 1-xxxxxxxxxxxxx (5α-xxxxxxx-1-xx-3,17-xxxx); bolandiol (estr-4-en-3β,17β-diol); xxxxxxxxxx; xxxxxxxx; xxxxxxx (xxxxxxxx-1,4-xxxx-3,17-xxxx); xxxxxxx (17α-xxxxxxx-17β-xxxxxxxxxxxxxx-4-xxx[2,3-x]xxxxxxxx); xxxxxxxxxxxxxxxxxxxxxxxxxxxxx (4-chloro-17β-hydroxy-17α-methylandrosta-1,4-dien-3-on); xxxxxxxxxxxxxxxxxxxxxxx (17α-xxxxxx-5α-xxxxxxx-2-xx-17β-xx); xxxxxxxxxxx; xxxxxxxxxxxxx (19-xxx-17α-xxxxx-4-xx-17-xx); xxxxxxxxxxxxxx; formebolon; xxxxxxxxx (17β-hydroxy-17α-methyl-5α-androstano[2,3-c]-furazan); gestrinon; 4-xxxxxxxxxxxxxxxxxx (4,17β-dihydroxyandrost-4-en-3-on); xxxxxxxxxx; xxxxxxxxx; xxxxxxxxxx; xxxxxxxxxx; xxxxxxxxxxx (17β-xxxxxxx-17α-xxxxxxxxxxxxxx-1,4-xxxx-3-xx); xxxxxxxxx; xxxxxxxxxxx; xxxxxxxxxx (2α, 17α-xxxxxxxx-5α-xxxxxxxxx-3-xx-17β-xx); xxxxxxxxxxxxxx (17β-xxxxxxx-17α-xxxxxxxxxxx-4,9-xxxx-3-xx); xxxxxx-1-xxxxxxxxxxx (17β-xxxxxxx-17α-xxxxxx-5α-xxxxxxx-1-xx-3-xx); methylnortestosteron (17β-xxxxxxx-17α-xxxxxxxxxx-4-xx-3-xx); xxxxxxxxxxxxxxxxx; xxxxxxxxxx (xxxxxxxxxxxxxxx (17β-hydroxy-17α-methylestra-4,9,11-trien-3-on); miboleron; xxxxxxxxx; 19-xxxxxxxxxxxxxxxx (xxxx-4-xx-3,17-xxxx); xxxxxxxxxx; xxxxxxxxxxxxxx; xxxxxxxxxxxx; xxxxxxxx; oxandrolon; oxymesteron; xxxxxxxxxx; prostanozol (17β-xxxxxxx-5α-xxxxxxxxxx [3,2-x]xxxxxxx); quinbolon; stanozolol; xxxxxxxxx; 1-testosteron (17β-xxxxxxx-5α-xxxxxxx-1-xx-3-xx); xxxxxxxxxxxxxxxxxxx (18α-xxxx-xxxxxx-4,9,11-xxxxx-17β-xx-3-xx); xxxxxxxxx x xxxxx látky x podobnou xxxxxxxxx xxxxxxxxxx nebo podobnými xxxxxxxxxxxx xxxxxx.
(x) Xxxxxxxxx** AAS, xxxxx xxxx xxxxxx exogenně:
Xxxxxxxxxxxxx (xxxxxxx-5-xx-3β,17β-xxxx), androstendion (xxxxxxx-4-xx-3,17-xxxx), xxxxxxxxxxxxxxxxxx, prasteron (xxxxxxxxxxxxxxxxxxxxx, DHEA, 3ß-xxxxxxxxxxxxxx-5-xx-17-xxx), xxxxxxxxxxx x xxxxxx xxxxxxxxxx a isomery, xxx ne x xxxxxxxx xxxxx xx xx:
| &xxxx;
5α-xxxxxxxxx-3α,17α-xxxx
|
&xxxx;
5-xxxxxxxxxxxxx (androst-5-en-3,17-dion)
|
|
5α-androstan-3α,17β-diol
|
|
|
5α-androstan-3β,17α-diol
|
epi-dihydrotestosteron
|
|
5α-androstan-3β,17β-diol
|
epitestosteron
|
|
androst-4-en-3α,17α-diol
|
3α-hydroxy-5αandrostan-17-on
|
|
androst-4-en-3α,17β-diol
|
3β-hydroxy-5αandrostan-17-on
|
|
androst-5-en-3β,17α-diol
|
7α-hydroxy-DHEA
|
|
androst-5-en-3α,17α-diol
|
7β-hydroxy-DHEA
|
|
androst-5-en-3α,17β-dioI
|
7-keto-DHEA
|
|
androst-5-en-3β,17α-diol
|
19-norandrosteron
|
|
4-androstendiol (androst-4-en-3β,17β-diol)
|
19-noretiocholanolon
|
2. Xxxxxxx xxxxxxxxxx xxxxx, xxxxxxxxxx:
Xxxxxxxxxxx, xxxxxxxxxx modulátory androgenových xxxxxxxxx (SARM), xxxxxxx, xxxxxxx, zilpaterol, ale xx x xxxxxxxx xxxxx xx xx.
| &xxxx;
Xxx xxxxx xxxxxxx této xxxxx: * "xxxxxxxx" xx xxxxxxxx k xxxxx, xxxxxx xxxx xxxx normálně xxxxxxx xxxxxxxxxx přirozeně. ** "xxxxxxxxx " xx xxxxxxxx x látce, xxxxxx může tělo xxxxxxxxxx xxxxxxxxx.
|
X2. PEPTIDOVÉ XXXXXXX, XXXXXXX FAKTORY X XXXXXXXX XXXXX
Xxxxxxxxxxx xxxxx x jejich xxxxxxxxxx faktory xxxx xxxxxxxx:
1. Xxxxx xxxxxxxxxxx erytropoesu (xxxx. xxxxxxxxxxxx (XXX), darbepoetin (xXXX), xxxxxxxxxxxxx xxxxxxx xxxxxxxxxxxxxx faktoru (HIF), xxxxxxxxxxxxxxxxxxxxxxxx-xxxxxxx xxxx (CERA), xxxxxxxxxxx /Hematide/);
2. Xxxxxxxxxxxxxxxxxx (CG) a Xxxxxxxxxxxx xxxxxx (XX) x mužů;
3. Xxxxxxxxxxxxxx;
4. Růstový xxxxxx (XX), fibroblastové xxxxxxx xxxxxxx (FGFs), xxxxxxxxxxxx xxxxxxx xxxxxx (XXX), xxxxxxxx podobný xxxxxxx faktor-1 (XXX-1), xxxxxxxxxx růstové xxxxxxx (XXX), xxxxxxx xxxxxx xxxxxxxx x xxxxxxxx xxxxxxxx (XXXX) x xxxxxxxxxx-xxxxxxxxxxxx xxxxxxx xxxxxx (XXXX), xxxxxx xxxx xxxxxxxxx xxxx růstové xxxxxxx ovlivňující syntézu xxxx xxxxxxxxx xxxxxxxx xxxxx, xxxxx x xxxxxx, xxxxxx xxxxxxxx, xxxxxxx xxxxxxx, xxxxxxxxxxxxx xxxxxxxx xxxx ovlivňující xxxx xxxxxxxxx vláken;
x další xxxxx x xxxxxxxx xxxxxxxxx xxxxxxxxxx nebo xxxxxxxxx xxxxxxxxxxxx xxxxxx.
X3. XXXX2- XXXXXXXX
Xxxxxxx xxxx-2 agonisté xxxxxx xxxx případných xxxxxxxxx xxxxxxx (xxxx. x- x l-), xxxx xxxxxxxx kromě xxxxxxxxxxx (xxxxxxxxx 1600 mikrogramů xx 24 xxxxx), xxxxxxxxxxx (xxxxxxxxx 36 xxxxxxxxxx za 24 xxxxx) x salmeterolu xxxxx xxxx xxxxxx x xxxxxxxx x xxxxxxx x doporučeným xxxxxxxx režimem výrobce.
Xxxxxxxxxx xxxxxxxxxxx x xxxx v xxxxxxxxxxx xxxxx než 1000 xx/xx x xxxxxxxxxx xxxxxxxxxxx v xxxx x koncentraci xxxxx xxx 40 ng/ml xxxxxx xxxxxxxxxx xx xxxxxxxxx terapeutické xxxxxxx, xxx bude xxxxxxxxxx xx pozitivní xxxxxxxxxxx xxxxx, xxxxx xxxxxxxxx xxxxxxxxx kontrolovanou xxxxxxxxxxxxxxxxx xxxxxx, xx xxxxxxxxxx xxxxxxxx xxx xxxxxxxx xxxxxxxx xxxxxxxxxxxx inhalační xxxxx nižší xxx xxxx uvedené maximum.
X4. XXXXXXXXX X XXXXXXXXXXX MODULÁTORY
Xxxxxxxx xx následující:
1. Xxxxxxxxxx xxxxxxxx, xxxxxxxxxx:
Xxxxxxxxxxxxxxxx, anastrozol, xxxxxxxx-1,4,6-xxxxx-3-17-xxxx (xxxxxxxxxxxxxxxxx), 4-xxxxxxxxx-3,6,17-xxxxx (6-oxo),exemestan, xxxxxxxxx, xxxxxxxx, xxxxxxxxxxx, xxx xx x xxxxxxxx pouze xx xx.
2. Selektivní xxxxxxxxxx xxxxxxxxxxxxx xxxxxxxxx (XXXX), xxxxxxxxxx:
Xxxxxxxxx, xxxxxxxxx, xxxxxxxxx, ale xx x xxxxxxxx xxxxx xx xx.
3. Ostatní xxxxxxxxxxxxxx xxxxx xxxxxxxxxx:
Cyklofenil, xxxxxxxxxxx, klomifen, ale xx x xxxxxxxx xxxxx xx ně.
4. Xxxxx xxxxxxxxxxxx xxxxxx xxxxxxxxxx včetně xxxxxxxxxx xxxxxxxxxx, xxx xx s xxxxxxxx xxxxx na ně.
5. Xxxxxxxxxxx xxxxxxxxxx:
x) Xxxxxxxx;
b) Xxxxxxxx xxxxx xxxxxxxxxx xxxxxxxxxxxxxx xxxxxxxxxxxxx /Xxxxxxxxxx Xxxxxxxxxxxx Xxxxxxxxx Receptor δ (PPARδ) agonists/ (xxxx. XX 1516) x Xxxxxxxx xxxxxxxxxxxxxxx xxx xxxxxxxxxx XXX x xxxxxxxxxxx s XXXX xxxxx /XXXXδ-XXX-xxxxxxxxx xxxxxxx kinase (XXXX) xxxx agonists/ (např. XXXXX)
X5. XXXXXXXXX X OSTATNÍ XXXXXXXXX XXXXX
Xxxxxxxxx xxxxx xxxx xxxxxxxx. Xxxxxxxx:
Xxxxxxxxx, desmopressin, xxxxxxxxxxxxxxx (xxxx. xxxxxxxx, nitrožilní xxxxxx xxxxxxxx, xxxxxxxx, xxxxxxxxxxxxxxxxxx a mannitolu), xxxxxxxxxx x xxxxx xxxxx x xxxxxxxxx xxxxxxxxxxxx xxxxxx. Xxxxxxx xxxxxx xxxxxxxxxxxx xxx xxxxx xxxxxxxx xxxx xxxxxxxx.
Xxxxxxxxx xxxxxxxx:
Xxxxxxxxxxxx, amilorid, xxxxxxxxx, xxxxxxxxx, xxxxxxxxxxxx, indapamid, xxxxxxxx, kyselina xxxxxxxxxx, xxxxxxxxx, xxxxxxxxxxxxx, xxxxxxxx (xxxx. xxxxxxxxxxxxxxxxxx, xxxxxxxxxxxxxxxxxx, xxxxxxxxxxxxx), triamteren x xxxxx látky x xxxxxxxx xxxxxxxxx strukturou xxxx xxxxxxxxx xxxxxxxxxxxx xxxxxx (xxxxx drospirenonu, xxxxxxxxx x lokálního xxxxxx dorzolamidu x xxxxxxxxxxxx, xxxxx xxxxxx xxxxxxxx).
Pro použití (Xxx Xxxxxxx, xxxxxxxx Xxxx Soutěž) jakéhokoliv xxxxxxxx xxxxx se xxxxxxxxxx xxxxxxxx xxxxxxx (xx. xxxxxxxxxx, xxxxxxxxxx, xxxxxx, xxxxx, xxxxxxx, xxxxxxxxxxxx x pseudoefedrin) xx xxxxxxx s xxxxxxxxxx xxxx xxxxx xxxxxxxxx xxxxxx je xxxxxxxxxx udělení xxxxxxxxxx Xxxxxxxxxxxx xxxxxxx xx xxxx xxxxx xxxxx x xx, která xxx xxxx xxxxxxx xx xxxxxxxxxx xxxx xxxxx xxxxxxxxx látku.
ZAKÁZANÉ XXXXXX
X1. XXXXXXXXXX X XXXX X XXXXXXXX XXXXXXXXXXXX
Xxxxxxxx xx xxxxxxxxxxx:
1. Xxxxxx nebo xxxxxxxxxxxxx xxxxxxxxx, homologní xxxx xxxxxxxxxxx krve xxxx xxxxxxxxx xxxxxxx x xxx xxxxxxxxx produktů xxxxxxxxxxx xxxxxx xx xxxxxxxxx systému.
2. Xxxxx xxxxxxxxx spotřeby, xxxxxxx nebo xxxxxxx xxxxxxx, xxxxxxxxxx xxxxxxxxxxxx xxxxxxxxxxxxx xxxxxxxx (např.krevní xxxxxxxx xxxxxxxx na xxxxxxxxxxx, xxxxxxxxxxxxxxxxxx hemoglobiny), xxxxxxxxxxxxxxxxxxx x xxxxxxxxxxx (XXX13), xxx ne x omezením pouze xx xx. Suplementace xxxxxxxx xxxxxxxx xxxx.
3. Xxxxxxxxx forma xxxxxxxxxxxxxxx manipulace x xxxx xxxx s xxxxxxxx xxxxxxxxxxxx fyzikálními xxxx xxxxxxxxxx xxxxxxx.
X2. XXXXXXXX X XXXXXXXXX XXXXXXXXXX
Zakázané xx následující:
1. Xxxxxxxxx, xxxx xxxxx x podvod, za xxxxxx xxxxxxx xxxxxxxxx x xxxxxxxx Xxxxxx xxxxxxxxxx xxx Xxxxxxxxx xxxxxxxx xx zakázané. Xx zahrnuje záměnu x/xxxx xxxxxx (např. xxxxxxxxxx) moči, xxx xx s omezením xxxxx xx xx.
2. Nitrožilní xxxxxx x/xxxx injekce xxxx xxx 50 ml xx 6 xxxxx xxxx xxxxxxxx xxxxx xxxxxx xxxxxxxxx přijatých x xxxxxxx xxxxxxxxxxxx xxxxxxx xxxx klinických xxxxxxxxxxxxx metod.
M3. XXXXXX XXXXXX
Z xxxxxx xxxxxxxxxx ke xxxxxxx xxxxxxxxxxx xxxxxx xx zakázáno následující:
1. Xxxxxxxx xxxxxxxxxx xxxxxxx xxxx jejich xxxxxxxx;
2. Použití xxxxxxxxxx nebo geneticky xxxxxxxxxxxxxx xxxxx;
| &xxxx;
XXXXX X METODY XXXXXXXX XXX XXXXXXX
|
Xxxxx xxxxxxxxx X0 xx X5 a X1 xx M3 xxxxxxxxx xxxx xxxx Xxx Xxxxxxx zakázané x následující xxxxxxx:
XXXXXXXX XXXXX
X6. XXXXXXXXXXX
Všechna xxxxxxxxxxx xxxxxx xxxxx xxxxxx xxxxxxxxxx xxxxxxxxx isomerů (xxxx. x- a x-) xxxx xxxxxxxx, x xxxxxxxx xxxxxxxx xxxxxxxxx x případě xxxxxx xxxxxxxx použití x xxxxxxxxxxx xxxxxxxxxx xx Xxxxxxxxxxxxxx programu xxx rok 2013*.
Xxxxxxxxxxx xxxxxxxx:
(a) Xxxxxxxxxxxx xxxxxxxxxxx:
Xxxxxxxxx, xxxxxxxxxx, amfetaminil, xxxxxxxxx, xxxxxxxxxx, benfluorex, xxxxxxxxxxx, xxxxxxxxxxxxxxx, xxxxxxxxx, xxxxxxxxxxxxxxxxx, xxxxxxxxxxxxxx, famprofazon, fendimetrazin, xxxxxxxxx, xxxxxxxxxxx, xxxxxxxx, xxxxxxxxxxx, xxxxxxxxxxx, xxxxxxxxx, 4-xxxxxxxxxxxxxx (karfedon), furfenorex, xxxxxxxxxxx, xxxxxx, xxxxxxxxxxx, xxxxxxxxxx, mefenorex, mefentermin, xxxxxxxxxxxx (x-), xxxxxxxxxxxxxxxxxxxxxx, xxxxxxxxxxxxxxxxxxxxxxxxx, mezokarb, xxxxxxxxx, xxxxxxxxxxxxxx, p-methylamfetamin, xxxxxxxxxx, xxxxxxxxx.
Xxxxxxxxxxxx, xxxxx xxxx xxxxxxxx xxxxxxx x xxxxx odstavci, xx Specifickou látkou.
(x) Specifická stimulancia (xxxxxxxx):
Adrenalin**, xxxxx***, xxxxxxx****, xxxxxxxx, xxxxxxxxx, xxxxxxxxxxx, fenkamfamin, xxxxxxxxxxxxx, xxxxxxxxxx, xxxxxxxxxxxx, xxxxxxxxxxxxxxx, xxxxxxxxxxxx, xxxxxxxxxxxx****, xxxxxxxxxxxxx, xxxxxxxxxxxxxxx (xxxxxxxxxxxxxxxxx), xxxxxxxxx, xxxxxxxxxxx, xxxxxxxxx, oxilofrin, xxxxxxxxxxxxxxxxxxxx, pemolin, xxxxxxxxxxx, xxxxxxxxxxxxxx, xxxxxxxxxxxxx*****xxxxxxxxx, xxxxxxxxxx, xxxxxxxxx, xxxxxxxxxxxxx x xxxxx xxxxx s xxxxxxxx xxxxxxxxx xxxxxxxxxx xxxx xxxxxxxxx biologickými xxxxxx.
* Xxxxxxxxxxx xxxxx zahrnuté xx Xxxxxxxxxxxxxx xxxxxxxx 2013 (xxxxxxxxx, xxxxxxxxxx, xxxxxxxxxxxxxxxxx, xxxxxx, nikotin, pipradrol, xxxxxxxx) nejsou xxxxxxxxxx xx Zakázané látky.
** Lokální xxxxxx xxxxxxxxxx (např. xxxxx, xxxx xxxxxxxx) xxxx xxxx podání společně x lokálními xxxxxxxxxx xxxx zakázáno.
*** Xxxxx je zakázaný xxxxx xxx xxxxxxxxxxx xxxxx než 5 xxxxxxxxxx x 1 xx xxxx.
**** Xxxxxxx x methylefedrin xxxx zakázány při xxxxxxxxxxx vyšší než 10 xxxxxxxxxx x 1 xx xxxx.
***** Xxxxxxxxxxxxx xx xxxxxxx, xxxxx xxxx xxxxxxxxxxx x xxxx xx xxxxx xxx 150 xxxxxxxxxx na xxxxxxxx
S7. XXXXXXXXX
Xxxxxxxx xx xxxxxxxxxxx:
Xxxxxxxxxxx, xxxxxxxxxxxxx, xxxxxxxxx(xxxxxx), xxxxxxxx a xxxx xxxxxxxx, hydromorfon, xxxxxxx, xxxxxx, oxykodon, xxxxxxxxx, xxxxxxxxxx, petidin.
S8. XXXXXXXXXXX
Xxxxxxxx (xxxx. xxxxx, xxxxxx x xxxxxxxxx) xxxx xxxxxxxxxx xxxxx9-xxxxxxxxxxxxxxxxxxx (XXX) x xxxxxxxxxxxxxx (xxxx. "Xxxxx" /XXX018, JWH073/ a XX-210) xxxx xxxxxxxx.
X9. XXXXXXXXXXXXXXXXXXXX
Xxxxxxx xxxxxxxxxxxxxxxxxxxx xxxxxxxx xxxxxx, xxxxxxxx, xxxxxxxxxx nebo xxxxxxxxxxxxx xxxxxxxx jsou xxxxxxxx.
| &xxxx;
XXXXX XXXXXXXX X XXXXXXXX XXXXXXXX
|
P1. ALKOHOL
Xxxxxxx (xxxxxx) xx xxxxxxxx pouze Xxx Xxxxxxx v xxxxxxxxxxxxx xxxxxxxx. Detekce se xxxx xxxxxxxx xxxxxxxx xxxxxxxx a/nebo rozborem xxxx. Xxxxxxx xxxxxxx xxx xxxxxxxx xxxxxxxxxxx xxxxxxxx (hematologická hodnota) xx 0.10 x/x.
∙ Automobilový sport (XXX)
∙ Karate (XXX)
∙ Xxxxxxx xxxxxx x xxxxxxxxxxxx(XXX)
∙ Lukostřelba (XXXX)
∙ Xxxxxxxxxxx xxxxx (XXX)
∙ Xxxxx xxxxxxxxxx (XXX)
X2. XXXX-XXXXXXXXX
Xxxxx není xxxxx xxxxxx, xxxx-xxxxxxxxx xxxx zakázány pouze Xxx Xxxxxxx x xxxxxxxxxxxxx sportech.
∙ Xxxxxxxxxxxx xxxxx (XXX)
∙ Xxxxxxxx (xxxxxxx xxxxxxxxxx) (XXXX)
∙ Xxxx (XXX)
∙ Xxxxxxxxxxx (XXXX, IPC) (xxxxxxxx xxxx Xxxx xxxxxx)
∙ Xxxxxxxx (XXX) - skoky xx lyžích x xxxxxxxxxxx lyžování-skoky x X-xxxxx,x xxxxxxxxx X-xxxxx x "xxx xxx"
∙ Xxxxxxx (XXXX, XXX) (xxxxxxxx xxxx Xxxx xxxxxx)
∙ Xxxxx (XXX)
Beta-blokátory xxxxxxxx xxxxxxxxxxx xxxxx:
Xxxxxxxxxx, xxxxxxxxxx, atenolol, xxxxxxxxx, xxxxxxxxxx, bunolol, xxxxxxxxxx, xxxxxxx, karteolol, xxxxxxxxxx, labetalol, xxxxxxxxxxx, xxxxxxxxxxxx, metoprolol, nadolol, xxxxxxxxxx, xxxxxxxx, xxxxxxxxxxx, xxxxxxx, timolol, xxx xx x xxxxxxxx xxxxx xx ně.
Xxxxxxxxx
Xxxxxx xxxxxxx x. 98/2013 Xx. x. x. nabyl xxxxxxxxx xxxx 20.12.2013.
Xxxxxx xxxxxxx x. 98/2013 Xx. x. x. xxx zrušen xxxxxxx xxxxxxxxx č. 47/2014 Sb. m. s. x xxxxxxxxx xx 20.9.2014.
Xxxxx xxxxxxxxxxxx xxxxxxxx xxxxx jiných xxxxxxxx xxxxxxxx v xxxxxxxx xxxx xxxxxxxxxxxxx, xxxxx xx xxxx xxxxxx derogační xxxxx xxxxx xxxxxxxxx xxxxxxxx xxxxxxxx.